Results 161 to 170 of about 53,202 (260)

Effect of GLP-1RA on mortality and cardiovascular risk in adults with psoriasis and type 2 diabetes. [PDF]

J Eur Acad Dermatol Venereol
Lin C, Braun N, Corey S, Thompson BB, Ma KS, Chen ST.   +5 more
europepmc   +1 more source

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, Volume 136, Issue 10, Page 4110-4111, October 2026.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8757-8768, October 2026.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series. [PDF]

Am J Case Rep
Chakrabarti MP, Han S, Campbell NM.
europepmc   +1 more source

Severity of Cardiovascular Autonomic Neuropathy Is Linked to Increasing Levels of Circulating Proinflammatory Cytokines

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8847-8860, October 2026.
ABSTRACT Aims Cardiovascular autonomic neuropathy (CAN) is a severe form of diabetic neuropathy affecting approximately one in five people with diabetes and is a major predictor of cardiovascular mortality. Low‐grade inflammation may contribute to CAN development, but the exact inflammatory factors associated with CAN remain unclear.
Michelle Damgaard, Marietta Kokla, Rebekka H. Gerwig, Hatice Isik Mizrak, Sofie Korsgaard Hecquet, Tik Muk, Gurjeet Kaur, Birgitte Brock, Christian Stevns Hansen, Joachim Størling   +9 more
wiley   +1 more source

Major Adverse Cardiovascular Events are Less Frequent in Psoriasis Patients Starting GLP-1RA Compared to Controls: An Observable Retrospective Cohort Study

Background: Psoriasis is an independent risk factor for major adverse cardiovascular events (MACE). We have previously shown that psoriasis patients with dyslipidemia have an increased incidence of MACE despite treatment with a biologic and a statin ...
Vera, Ana Ormaza, Olexson, Madison, Choi, June, Enos, Clinton, Osorlo, Marla F., Ro, Chunghwan   +5 more
core  

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8769-8776, October 2026.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In Vivo. [PDF]

Int J Mol Sci
Thome AD, Wang J, Faridar A, Zhao W, Saetzler V, Beers DR, Appel SH.   +6 more
europepmc   +1 more source

GLP-1RA: New Hope in Obesity Therapy

Journal of Biosciences and Medicines
Danfeng Zhang, Hongyun Lu
openaire   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8812-8824, October 2026.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source